§
Luxuse
Patent Intelligence
Sign In
← Back to Patent Explorer
EP0281380A2 Expired / Lapsed EP ⏱️ 0.0 years remaining

Synergistic interplay of interleukin-2 and dsRNAs

Assignee: HEM Pharmaceuticals Corp
•
Filing: 1988-03-02
•
Granted: —
•
Expires: 2008-03-02
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The unexpected synergistic interplay between lymphokines and dsRNAs which dramatically reduces the necessary dosages of lymphokines, especially IL-2, and simultaneously widens their therapeutic range in the treatment of various types of cancers, viral disorders or other body conditions characterized by disregulated immune states (e.g., autoimmune diseases). Specific combinations of dsRNA plus IL-2 significantly increase survival in human melanoma-bearing animals in part because of augmentation by dsRNA of lymphokine activated killer cells (LAK) which are first formed in response to IL-2 exposure. The invention has wide applicability to non-toxic, efficacious control of both human cancer and various human viral infections and immunoregulatory disorders.

Inventors

  • 👤 William A. Carter

Bibliographic Details

Application Number —
Jurisdiction EP
Data Source google_patents
Last Synchronized 2026-11-07 13:55
CPC Classifications
A; A61; A61K; A61K45/00; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/21; A61K38/212; A61K38/20; A61K38/2013; A61P; A61P29/00; A61P31/00; A61P31/12; A61P35/00; A61P37/00

Claims Analysis

Total Claims: 11
Claim 1
Independent Claim 25 words
Product containing dsRNA and a lymphokine as a combined preparation for simultaneous, separate or sequential use in the treatment of tumour, virus-infected or immune-disregulated cells.
Claim 2
Dependent Claim 25 words
Product containing dsRNA and a lymphokine as a combined preparation for simultaneous, separate or sequential use in the treatment of tumour, virus-infected or immune-disregulated cells.
Claim 3
Dependent Claim 15 words
The product of claim 1, which is a therapeutic composition comprising dsRNA and a lymphokine.
Claim 4
Dependent Claim 16 words
The product of claim 1 or claim 2, further comprising a substance which inhibits cyclooxygenase activator
Claim 5
Dependent Claim 16 words
The product of claim 3, in which the inhibitor suppresses the NK cell down regulation mechanism.
Claim 6
Dependent Claim 16 words
The product of any one of claims 1 to 4, wherein the dsRNA is mismatched dsRNA.
Claim 7
Dependent Claim 14 words
The product of claim 5, wherein the dsRNA is of the general formula rIn.(C₁₂U)n.
Claim 8
Dependent Claim 19 words
The product of any one of claims 1 to 6, wherein the lymphokine is an interferon or an interleukin.
Claim 9
Dependent Claim 14 words
The product of claim 7, wherein the lymphokine is alpha interferon or interleukin 2.
Claim 10
Dependent Claim 47 words
The product of any one of claims 1 to 8, comprising sufficient concentrations of the dsRNA and the lymphokine to result in enhanced levels of both NK and LAK cells in the treated subject without increased toxicity in excess of that of the dsRNA or the lymphokine.
Claim 11
Dependent Claim 62 words
The product of claim 1 or claim 2 wherein the dsRNA is mismatched dsRNA in an amount sufficient to result in a level of 0.01 to 1000 µg/ml of the patient's body fluid, and wherein the lymphokine is interleukin-2 in an amount sufficient to result in a level of from about 10² to 10⁶ IL-2 units per kilogram of the patient's weight.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Maintenance schedule is calculated for granted US utility patents.

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag